Cargando…

妊娠期停用酪氨酸激酶抑制剂对慢性髓性白血病患者疾病状态及生育结果影响的观察

OBJECTIVE: To explore the pregnancy outcome and disease status among patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitor (TKI) when they stopped TKI treatment during pregnancy. METHODS: The clinical characteristics, reproductive outcomes and disease status of the pati...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342204/
https://www.ncbi.nlm.nih.gov/pubmed/30122011
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.07.003
_version_ 1783555403250925568
collection PubMed
description OBJECTIVE: To explore the pregnancy outcome and disease status among patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitor (TKI) when they stopped TKI treatment during pregnancy. METHODS: The clinical characteristics, reproductive outcomes and disease status of the patients who stopped TKI due to pregnancy between November 2004 to November 2017 were retrospectively collected. RESULTS: A total of 14 CML patients in chronic phase (CML-CP), 12 patients were Sokal-low-risk. The median time of TKI treatment was 46.5 (15–123) months before the drug was stopped. The median age at the time of pregnancy was 29 (24–32) years. The median time of TKI exposure was 4 (0–9) weeks in 12 accidental pregnancies. Outcomes were available for 13 pregnancies, 9 cases (69.2%) delivered healthy babies, 1 case (7.7%) delivered polydactylia malformation baby, 3 cases (23.1%) had spontaneous abortion. The last one was still in pregnancy (no organ malformations were observed in color Doppler ultrasound). At the end of the follow up date, 10 children developed normal, the median age was 14 (0.7–65) months. Of the 14 patients who stopped TKI, 7 in complete molecular response (CMR), 3 in MR(4) (BCR-ABL(IS) <0.01%, ABL transcript >10 000), 2 in major molecular response (MMR), 2 in complete cytogenetic response (CCyR). The median time of TKI discontinuation during pregnancy was 33.5 (4–40) weeks. At the end of pregnancy, 4 cases were in CMR, 4 in MR(4), 1 in MMR and 4 in CCyR. No patients lost CCyR and complete hematologic remission. CONCLUSION: During the treatment of imatinib and Nilotinib, unplanned pregnancy may have a normal infant, but may lead to spontaneous abortion and congenital malformations. Female of CML-CP who had sustained and stable MMR at least 24 months and Sokal-low-risk had higher safety factor discontinued TKI during pregnancy, but still had a risk of increasing tumor load, so monitored the level of BCR-ABL of peripheral blood monthly during pregnancy is necessary.
format Online
Article
Text
id pubmed-7342204
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73422042020-07-16 妊娠期停用酪氨酸激酶抑制剂对慢性髓性白血病患者疾病状态及生育结果影响的观察 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the pregnancy outcome and disease status among patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitor (TKI) when they stopped TKI treatment during pregnancy. METHODS: The clinical characteristics, reproductive outcomes and disease status of the patients who stopped TKI due to pregnancy between November 2004 to November 2017 were retrospectively collected. RESULTS: A total of 14 CML patients in chronic phase (CML-CP), 12 patients were Sokal-low-risk. The median time of TKI treatment was 46.5 (15–123) months before the drug was stopped. The median age at the time of pregnancy was 29 (24–32) years. The median time of TKI exposure was 4 (0–9) weeks in 12 accidental pregnancies. Outcomes were available for 13 pregnancies, 9 cases (69.2%) delivered healthy babies, 1 case (7.7%) delivered polydactylia malformation baby, 3 cases (23.1%) had spontaneous abortion. The last one was still in pregnancy (no organ malformations were observed in color Doppler ultrasound). At the end of the follow up date, 10 children developed normal, the median age was 14 (0.7–65) months. Of the 14 patients who stopped TKI, 7 in complete molecular response (CMR), 3 in MR(4) (BCR-ABL(IS) <0.01%, ABL transcript >10 000), 2 in major molecular response (MMR), 2 in complete cytogenetic response (CCyR). The median time of TKI discontinuation during pregnancy was 33.5 (4–40) weeks. At the end of pregnancy, 4 cases were in CMR, 4 in MR(4), 1 in MMR and 4 in CCyR. No patients lost CCyR and complete hematologic remission. CONCLUSION: During the treatment of imatinib and Nilotinib, unplanned pregnancy may have a normal infant, but may lead to spontaneous abortion and congenital malformations. Female of CML-CP who had sustained and stable MMR at least 24 months and Sokal-low-risk had higher safety factor discontinued TKI during pregnancy, but still had a risk of increasing tumor load, so monitored the level of BCR-ABL of peripheral blood monthly during pregnancy is necessary. Editorial office of Chinese Journal of Hematology 2018-07 /pmc/articles/PMC7342204/ /pubmed/30122011 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.07.003 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
妊娠期停用酪氨酸激酶抑制剂对慢性髓性白血病患者疾病状态及生育结果影响的观察
title 妊娠期停用酪氨酸激酶抑制剂对慢性髓性白血病患者疾病状态及生育结果影响的观察
title_full 妊娠期停用酪氨酸激酶抑制剂对慢性髓性白血病患者疾病状态及生育结果影响的观察
title_fullStr 妊娠期停用酪氨酸激酶抑制剂对慢性髓性白血病患者疾病状态及生育结果影响的观察
title_full_unstemmed 妊娠期停用酪氨酸激酶抑制剂对慢性髓性白血病患者疾病状态及生育结果影响的观察
title_short 妊娠期停用酪氨酸激酶抑制剂对慢性髓性白血病患者疾病状态及生育结果影响的观察
title_sort 妊娠期停用酪氨酸激酶抑制剂对慢性髓性白血病患者疾病状态及生育结果影响的观察
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342204/
https://www.ncbi.nlm.nih.gov/pubmed/30122011
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.07.003
work_keys_str_mv AT rènshēnqītíngyònglàoānsuānjīméiyìzhìjìduìmànxìngsuǐxìngbáixuèbìnghuànzhějíbìngzhuàngtàijíshēngyùjiéguǒyǐngxiǎngdeguānchá
AT rènshēnqītíngyònglàoānsuānjīméiyìzhìjìduìmànxìngsuǐxìngbáixuèbìnghuànzhějíbìngzhuàngtàijíshēngyùjiéguǒyǐngxiǎngdeguānchá
AT rènshēnqītíngyònglàoānsuānjīméiyìzhìjìduìmànxìngsuǐxìngbáixuèbìnghuànzhějíbìngzhuàngtàijíshēngyùjiéguǒyǐngxiǎngdeguānchá
AT rènshēnqītíngyònglàoānsuānjīméiyìzhìjìduìmànxìngsuǐxìngbáixuèbìnghuànzhějíbìngzhuàngtàijíshēngyùjiéguǒyǐngxiǎngdeguānchá
AT rènshēnqītíngyònglàoānsuānjīméiyìzhìjìduìmànxìngsuǐxìngbáixuèbìnghuànzhějíbìngzhuàngtàijíshēngyùjiéguǒyǐngxiǎngdeguānchá
AT rènshēnqītíngyònglàoānsuānjīméiyìzhìjìduìmànxìngsuǐxìngbáixuèbìnghuànzhějíbìngzhuàngtàijíshēngyùjiéguǒyǐngxiǎngdeguānchá
AT rènshēnqītíngyònglàoānsuānjīméiyìzhìjìduìmànxìngsuǐxìngbáixuèbìnghuànzhějíbìngzhuàngtàijíshēngyùjiéguǒyǐngxiǎngdeguānchá
AT rènshēnqītíngyònglàoānsuānjīméiyìzhìjìduìmànxìngsuǐxìngbáixuèbìnghuànzhějíbìngzhuàngtàijíshēngyùjiéguǒyǐngxiǎngdeguānchá
AT rènshēnqītíngyònglàoānsuānjīméiyìzhìjìduìmànxìngsuǐxìngbáixuèbìnghuànzhějíbìngzhuàngtàijíshēngyùjiéguǒyǐngxiǎngdeguānchá